Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Citron Research

Long Bitcoin, Short MicroStrategy: Citron Research 'Proud Of The Timing' One Year Later

Short seller Citron Research, led by Andrew Left, made a prediction one year ago. The firm bet on Bitcoin (CRYPTO: BTC), but against the Bitcoin treasury company Strategy Inc (NASDAQ:MSTR). Here are the results of the trade.

Trump Just Made This The 'Most Important Company In America,' Says Andrew Left: 'That Nobody's Heard Of...'

Trump Just Made This The 'Most Important Company In America,' Says Andrew Left: 'That Nobody's Heard Of...'

Andrew Left’s Citron Research is calling out a little-known nuclear contractor, which it says is about to become one of the most strategically significant companies in the United States under the Trump administration.

Nvidia Hits $5 Trillion: Is This The Next Dot-Com Bubble Or AI Gold Rush? The 56x Return Investor Speaks

Nvidia Hits $5 Trillion: Is This The Next Dot-Com Bubble Or AI Gold Rush? The 56x Return Investor Speaks

As chipmaker NVIDIA Corp. (NASDAQ:NVDA) surges past $5 trillion in market capitalization, several prominent analysts have reacted to the stock’s unrelenting rally, amid growing concerns regarding its sustainability and speculations of an AI bubble.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

What's Going On With Bleichroeder Acquisition Corp (BACQ) Stock Today?

Bleichroeder Acquisition Corp (NASDAQ:BACQ) shares are trending higher Thursday following commentary from Citron Research highlighting the SPAC’s risk-reward profile.

Rigetti Vs. Infleqtion: Citron Weighs In On Quantum 'Raging Bulls'

Citron Research's assessment of Rigetti Computing Inc. (NASDAQ:RGTI) versus Infleqtion, the quantum technology firm set to merge with Churchill Capital Corp X (NASDAQ:CCCX), has "raging" quantum bulls locking horns.

Teladoc (TDOC) Shares Climb On Bullish Commentary From Citron Research

Shares of Teladoc Health Inc (NYSE:TDOC) are surging Friday morning after Citron Research posted bullish comments on the telehealth provider, asserting they were “not wrong, just early” on the stock’s potential. The commentary sparked renewed investor interest, pushing the stock higher in early trading.

Cardlytics Stock Surges 5% After Hours As Citron Research Spotlights Wells Fargo Partnership

Cardlytics Inc. (NASDAQ: CDLX) saw its stock fall 9.85% during regular trading on Thursday. However, the stock rebounded in after-hours trading, climbing 5.04% to $2.50 following positive remarks from analysts.

inkl

Read news from The Economist, FT, and more,
with one subscription

Cardlytics Stock Soars After Citron Research Says Shares Could 'Double Or Triple' From Here

Cardlytics Stock Soars After Citron Research Says Shares Could 'Double Or Triple' From Here

Shares of Cardlytics, Inc. (NASDAQ:CDLX) are rising on Wednesday after a research firm published a glowing report on the company, which partners with retail outlets and banks to offer cash-back rewards on card purchases.

Cardlytics (CDLX) Stock Soars Over 50% On AmEx News And Citron Tweet

Cardlytics (CDLX) Stock Soars Over 50% On AmEx News And Citron Tweet

Shares of advertising-platform Cardlytics Inc (NASDAQ:CDLX) are surging Thursday morning. The rally was ignited by a bullish tweet from Citron Research connecting Cardlytics to news of the American Express Co (NYSE:AXP) Platinum card refresh.

Pharma Bro Martin Shkreli Confirms Shorting Opendoor, Plans Public Due Diligence Campaign Into The Firm: 'I Shorted $OPEN'

Pharma Bro Martin Shkreli Confirms Shorting Opendoor, Plans Public Due Diligence Campaign Into The Firm: 'I Shorted $OPEN'

Martin Shkreli, also popularly known as ‘Pharma Bro,’ announced late Tuesday that he has taken a short position against iBuying real estate company Opendoor Technologies Inc. (NASDAQ:OPEN).

Elon Musk's Two-Word Response, Trump Administration's Patent Share, Palantir CEO's China Warning And More: This Week In Politics

Elon Musk's Two-Word Response, Trump Administration's Patent Share, Palantir CEO's China Warning And More: This Week In Politics

It’s been an eventful week, with some of the most influential figures in the business world making headlines. Here’s a quick recap of the top political stories you might have missed.

Trump-Linked Mortgage Trade? Citron Says This Stock Is A Soldier In 'War On Housing' — Predicts 91% Upside

Trump-Linked Mortgage Trade? Citron Says This Stock Is A Soldier In 'War On Housing' — Predicts 91% Upside

Andrew Left’s Citron Research is making a bold new bet in the housing finance space, framing it as a deep-value play, and one that is likely to play a central role in President Donald Trump’s new housing policy.

Short Seller Andrew Left Recalls Bet On Nebius As It Soars Over 130% In 2025: 'Just A Pat On The Back' From When NBIS Was At $20 Per Share

Short Seller Andrew Left Recalls Bet On Nebius As It Soars Over 130% In 2025: 'Just A Pat On The Back' From When NBIS Was At $20 Per Share

Famed short-seller Andrew Left of Citron Research is taking a victory lap on a bullish call, celebrating his firm’s early bet on AI infrastructure company Nebius Group NV (NASDAQ:NBIS).

Martin Shkreli Doubles Down On Opendoor 'Short' Call: 'Pharma-Bro' Draws Parallels With Newegg — 'Game Over Losers'

Martin Shkreli Doubles Down On Opendoor 'Short' Call: 'Pharma-Bro' Draws Parallels With Newegg — 'Game Over Losers'

Former hedge fund manager and pharmaceutical executive, Martin Shkreli, doubled down on his bearish stance against Opendoor Technologies Inc. (NASDAQ:OPEN), drawing parallels with another retail favorite stock that has since witnessed a pullback.

Get all your
news in one place.

100’s of premium titles.
One news app.

Opendoor Attacked By Short Seller—Stock Pops Anyway

Citron Research, led by famed short-seller Andrew Left, targeted Opendoor Technologies, Inc. (NASDAQ:OPEN) in a social media post on Friday. Opendoor investors shrugged off the attack, and the stock climbed.

Palantir's AI Edge: PEG Ratio Outshines Salesforce—'Sleeper Valuation' Defying P/E Skeptics?

In a landscape where high Price-to-Earnings (P/E) ratios often scare investors, a different metric defies skeptics that AI powerhouse, Palantir Technologies Inc. (NASDAQ:PLTR), which was battered last week for its high valuations following a Citron Research report, is not quite overpriced.

Palantir's 70x Revenue Valuation May Be Unsustainable Despite 'Outstanding Q2 Results' — Citi Analyst Warns Company's 'Edge' May Fade As AI Expands

According to Tyler Radke, a senior Citigroup equity analyst, Palantir Technologies Inc.’s (NASDAQ:PLTR) lofty valuations are difficult to justify despite its “outstanding Q2 results.”

Palantir Short Seller Andrew Left's Citron Now Compares It To Databricks: 'PLTR Is A $40 Stock, And Every Real AI Leader Keeps Reminding Us'

Short-seller Andrew Left‘s Citron Research intensified its campaign against Palantir Technologies Inc. (NYSE:PLTR) on Wednesday, posting a direct comparison to private competitor Databricks that highlights Palantir’s slower growth on several key metrics.

Get all your
news in one place.

100’s of premium titles.
One news app.

Palantir Continues To Decline In Pre-Market As Valuation Concerns Mount—Citron Research Targets Overvaluation

Palantir Technologies Inc. (NASDAQ:PLTR) declined 0.95% to $156.08 during pre-market on Wednesday, extending its 9.35% drop from Tuesday's regular trading, despite expanding its partnership with Fujitsu Ltd.

Palantir Stock Is Trending Tuesday: What's Going On?

Palantir Technologies Inc (NASDAQ:PLTR) is trading lower on Tuesday as selling pressure and weaker momentum indicators weighed on investor sentiment. Valued at $412 billion, Palantir’s market cap has soared despite generating only $1.7 billion in free cash flow, making it appear as though it has “invented time travel” in the…

Short Seller Andrew Left Says 'OpenAI At $500 Billion Puts Palantir At $40' — And That's Generous

Renowned short-seller Andrew Left's Citron Research has issued a bearish report on Palantir Technologies Inc. (NASDAQ:PLTR), arguing the stock is significantly overvalued and its price is "detached from fundamentals and analysis".

Citron Research Just Warned AGAIN on Palantir. How Should You Play PLTR Stock Here?

Citron Research says Palantir stock at $40 per share would still be an expensive AI stock to own. Wall Street recommends caution on PLTR shares as well.

Short Seller Slams Jim Cramer Over Palantir, Accuses Him Of Hyping 'High-Multiple, Hype-Driven Narrative' After $200 Price Target Call

Famed short-seller Andrew Left's Citron Research publicly challenged CNBC's Jim Cramer over his bullish stance on Palantir Technologies Inc. (NASDAQ:PLTR).

GameStop Short Seller Andrew Left Is Taking On Retail Investors Again, Now Says Palantir Stock Is 'Beyond Overvalued'

Citron Research founder and famed short seller Andrew Left announced a new short pick on Wednesday during an appearance on Fox Business.

Andrew Left Doubles Down On Rocket Companies: 'This Isn't A Meme,' It's A 'Housing Juggernaut' In The Making (CORRECTED)

Editor's Note: This article has been updated to correct the individual’s name in the headline.

People

156,487 stories

Spencer Hakimian

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Trump Administration

American Express

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

325,826 stories

The United States

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play